U.S. markets close in 3 hours 10 minutes
  • S&P 500

    3,775.13
    +96.70 (+2.63%)
     
  • Dow 30

    30,206.01
    +715.12 (+2.42%)
     
  • Nasdaq

    11,129.81
    +314.38 (+2.91%)
     
  • Russell 2000

    1,770.43
    +61.56 (+3.60%)
     
  • Crude Oil

    86.42
    +2.79 (+3.34%)
     
  • Gold

    1,737.30
    +35.30 (+2.07%)
     
  • Silver

    21.28
    +0.70 (+3.38%)
     
  • EUR/USD

    0.9973
    +0.0146 (+1.49%)
     
  • 10-Yr Bond

    3.6090
    -0.0420 (-1.15%)
     
  • GBP/USD

    1.1454
    +0.0135 (+1.19%)
     
  • USD/JPY

    144.1300
    -0.4900 (-0.34%)
     
  • BTC-USD

    20,025.29
    +637.38 (+3.29%)
     
  • CMC Crypto 200

    455.34
    +9.90 (+2.22%)
     
  • FTSE 100

    7,086.46
    +177.70 (+2.57%)
     
  • Nikkei 225

    26,992.21
    +776.42 (+2.96%)
     

Adicet Bio (NASDAQ:ACET) shareholders have endured a 27% loss from investing in the stock a year ago

·2 min read

It is doubtless a positive to see that the Adicet Bio, Inc. (NASDAQ:ACET) share price has gained some 35% in the last three months. But that is minimal compensation for the share price under-performance over the last year. In fact the stock is down 27% in the last year, well below the market return.

It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that.

View our latest analysis for Adicet Bio

Adicet Bio isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

In just one year Adicet Bio saw its revenue fall by 33%. That's not what investors generally want to see. The stock price has languished lately, falling 27% in a year. That seems pretty reasonable given the lack of both profits and revenue growth. We think most holders must believe revenue growth will improve, or else costs will decline.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

Take a more thorough look at Adicet Bio's financial health with this free report on its balance sheet.

A Different Perspective

Given that the market gained 30% in the last year, Adicet Bio shareholders might be miffed that they lost 27%. While the aim is to do better than that, it's worth recalling that even great long-term investments sometimes underperform for a year or more. Putting aside the last twelve months, it's good to see the share price has rebounded by 35%, in the last ninety days. Let's just hope this isn't the widely-feared 'dead cat bounce' (which would indicate further declines to come). I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 4 warning signs for Adicet Bio you should be aware of, and 2 of them are significant.

Of course Adicet Bio may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.